With the evolving landscape and investor outlook and the challenges of developing new technologies and assets in the current biotech environment, this is an insightful and in-depth roundtable discussion with Syneos Health® and one of their strategic partners, TreeHill Partners, focusing on the key areas which should be considered by biotech companies to ensure they give themselves the best chance of success with potential investors and in terms of their asset development and corporate goals in 2024 and beyond.
- Member community
- Membership application
- About SwedenBIO
- About SwedenBIOSwedenBIO är branschorganisationen för life science-industrin. Vi skapar effektiva kontaktytor, bygger kunskap och ger branschen en stark röst.
- Contact us